סנדוסטטין 0.2 מגמל

Country: Israel

Language: Hebrew

Source: Ministry of Health

Active ingredient:

OCTREOTIDE

Available from:

NOVARTIS ISRAEL LTD

ATC code:

H01CB02

Pharmaceutical form:

תמיסה להזרקה\אינפוזיה

Composition:

OCTREOTIDE 0.2 MG/ML

Administration route:

תת-עורי, תוך-ורידי

Prescription type:

מרשם נדרש

Manufactured by:

NOVARTIS PHARMA STEIN AG, SWITZERLAND

Therapeutic group:

OCTREOTIDE

Therapeutic area:

OCTREOTIDE

Therapeutic indications:

Prevention of complications following pancreatic surgery. Symptomatic control and reduction of GH and IGF-1plasma levels in patients with acromegaly who are inadequately controlled by surgery or radiotherapy. Sandostatin treatment is also indicated for acromegalic patients unfit or unwilling to undergo surgery or in the interim period until radiotherapy becomes fully effective. Relief of symptoms associated with functional gastroenteropancreatic endocrine tumours: - Carcinoid tumours with features of the carcinoid syndrome - VIPomas - Glucagonomas - Gastrinomas / zollinger-Ellison syndrome usually in conjunction with proton pump inhibitors or H2- antagonist therapy - Insulinomas for pre-operative control of hypoglycaemia and for maintenance therapy - GRFomas. Sandostatin is not an antitumour therapy and is not curative in these patients.Emergency management of bleeding gastro-oesophageal varices secondary to cirrhosis in combination with specific therapy such as endoscopic sclerotherapy.

Authorization date:

2010-03-31